New hope for chinese MS patients: fingolimod shows promise in reducing relapses
NCT ID NCT04667949
First seen Jan 11, 2026 · Last updated May 19, 2026 · Updated 15 times
Summary
This study looked at how well and how safely the drug fingolimod (Gilenya) works for people in China with relapsing multiple sclerosis (RMS). It included 98 patients aged 10 to 65 who had never taken fingolimod before. Over 24 months, researchers measured the number of MS relapses and tracked any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS (RMS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Beijing, Beijing Municipality, 100000, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510623, China
-
Novartis Investigative Site
Guangzhou, Guangdong, 510630, China
-
Novartis Investigative Site
Zhengzhou, Henan, 450052, China
-
Novartis Investigative Site
Wuhan, Hubei, 430030, China
-
Novartis Investigative Site
Suzhou, Jiangsu, 215004, China
-
Novartis Investigative Site
Changchun, Jilin, 130021, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Wenzhou, Zhejiang, 325000, China
-
Novartis Investigative Site
Beijing, 065001, China
-
Novartis Investigative Site
Beijing, 100028, China
-
Novartis Investigative Site
Guangzhou, 510260, China
-
Novartis Investigative Site
Shanghai, 200040, China
Conditions
Explore the condition pages connected to this study.